PLEASANTON, CALIF., NANJING, CHINA, June 15, 2021 – IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases today announced the appointment of David He, Ph.D., as Chief Technology Officer (CTO) and Executive Vice President, reporting to Maxwell Wang, M,D., CEO of IASO bio. As a member of the executive leadership team, Dr. He will oversee the company's global process development, Chemistry, Manufacturing and Controls (CMC), and quality control activities and will work closely with the R&D, clinical, regulatory and business development team to prioritize drug development and formulate strategies.
Dr. He brings to IASO bio more than 30 years of experience with an excellent track record of successfully developing novel oncology therapies and biomedical research. He has extensive experience in the process development and GMP production of cellular immunotherapies and biological products. Previously, Dr. He held leadership positions in innovative biotech or global pharmaceutical company such as Clover Bio, Legend Bio, and Boehringer Ingelheim in China and the United States. As a key decision maker, he led technical operations teams in successfully achieving GMP compliant manufacturing and BLA filing in accordance with FDA/ NMPA/ EMA/ ICH guidelines. David holds a Ph.D. in Pathogenic Biology from Sun Yat-sen University, and completed postdoctoral research in immunology at the University of Alabama at Birmingham.
"I am honored to serve as IASO bio’s Chief Technology Officer. I have been incredibly impressed with the capability and productivity of IASO’s extremely talented and passionate team, as well as a number of promising fully human potential Best-in-Class and First-In-Class drug candidates. The company’s pipeline covers multiple therapeutic areas and is comprised of differentiated products, with CAR-T cell therapy as a good example of fast to market product. CT103A, IASO’s lead product, has received the Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA). As the company is currently in a critical period of moving from clinical to commercialization stage, I am very much looking forward to working with the team in order to help accelerating the commercialization process of IASO’s innovative drugs. In line with the company’s innovation and entrepreneurship spirit, by improving the company’s technology development platform, commercial production platform, and quality management system, we together can achieve the company’s mission of benefiting more patients around the world", said Dr. He.
Dr. Maxwell Wang, CEO of IASO Bio, said, "We’d like to extend our welcome to Dr. David He as he joins IASO Bio. Dr. He's experience in process development and manufacture of cell therapies and biological products are very valuable to the company. After four years of rapid progress, IASO Bio has established an integrated capabilities from early discovery, R&D, clinical development, to commercialization. Meanwhile, a “two-track” development pattern has formed with collaborative development of cell therapies and biological products. At present, IASO Bio’s commercialization facility of more than 10,000 square meters in Nanjing is already operational, and the company’s Global R&D headquarters and development base in the Shanghai Waigaoqiao Free Trade Area will soon be completed in 2022. IASO's process development and production team is one of the few domestic teams with pivotal study production experiences. Dr. He’s successful track record in navigating all stages of product development will help us effectively execute our later stage development plans of cell therapies and biological products, and lead our process and production team to continue to improve, and to promote the commercial launch of more innovative therapies."
About IASO Bio
IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput CAR-T drug priority platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biological product candidates. Currently, the company is developing a diversified portfolio of over 10 novel pipeline products. IASO’s leading asset, CT103A, an innovative anti-BCMA CAR T- cell therapy under pivotal study for relapsed/refractory multiple myeloma (R/R MM), was granted Breakthrough Therapeutic Designation (BTD) by China’s National Medical Products Administration (NMPA) in February 2021. For more information on IASO, please visit www.iasobio.com.
